Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, et al.
Schizophrenia Research (2021) Vol. 228, pp. 198-205
Open Access | Times Cited: 24

Showing 24 citing articles:

New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
Aineng Peng, Chai Jian-bo, Haiyuan Wu, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 607-620
Open Access | Times Cited: 10
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Marco Solmi, Alessandro Miola, Federico Capone, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1249-1269
Closed Access | Times Cited: 6
New Antipsychotic Medications in the Last Decade
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, et al.
Current Psychiatry Reports (2021) Vol. 23, Iss. 12
Closed Access | Times Cited: 35
Antipsychotic-Induced Metabolic Syndrome: A Review
Samuel Akinola, Isabelle Tardif, Jacinthe Leclerc
Metabolic Syndrome and Related Disorders (2023) Vol. 21, Iss. 6, pp. 294-305
Closed Access | Times Cited: 16
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
Matej Ľupták, Danica Michaličková, Zdeněk Fišar, et al.
World Journal of Psychiatry (2021) Vol. 11, Iss. 7, pp. 277-296
Open Access | Times Cited: 30
The role of lumateperone in the treatment of schizophrenia
Alveena Batool Syed, James Robert Brašić
Therapeutic Advances in Psychopharmacology (2021) Vol. 11
Open Access | Times Cited: 28
Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism
Joep Titulaer, O. Radhe, Klara Danielsson, et al.
European Neuropsychopharmacology (2022) Vol. 62, pp. 22-35
Open Access | Times Cited: 20
Seventy Years of Antipsychotic Development: A Critical Review
Mujeeb U. Shad
Biomedicines (2023) Vol. 11, Iss. 1, pp. 130-130
Open Access | Times Cited: 12
Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features
Suresh Durgam, S.G. Kozauer, Willie Earley, et al.
Journal of Clinical Psychopharmacology (2025)
Closed Access
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial
Zahra Hosseinnia, Mobina Amanollahi, Bahareh Ahli, et al.
International Clinical Psychopharmacology (2025)
Closed Access
New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?
Paola Bozzatello, Roberta Novelli, Rebecca Schisano, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 5, pp. 665-665
Open Access
Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences
Gloria Munayco Maldonado, Thomas L. Schwartz
International Clinical Psychopharmacology (2023) Vol. 39, Iss. 1, pp. 4-16
Closed Access | Times Cited: 6
Lumateperone for the Treatment of Schizophrenia
Leslie Citrome, Suresh Durgam, J.B. Edwards, et al.
The Journal of Clinical Psychiatry (2023) Vol. 84, Iss. 2
Open Access | Times Cited: 5
Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review
Muhammad Youshay Jawad, Yazen Alnefeesi, Felicia Ceban, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 8, pp. 359-368
Closed Access | Times Cited: 8
Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
Yanjing Zhang, Chunhua Zhou, Yan Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
Rajdip Barman, Pradipta Majumder, Tejaswini Doifode, et al.
World Journal of Psychiatry (2021) Vol. 11, Iss. 12, pp. 1228-1238
Open Access | Times Cited: 9
Recent Advances in Psychopharmacology: From Bench to Bedside Novel Trends in Schizophrenia
Asim A. Shah, Syed Iqbal
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 411-411
Open Access | Times Cited: 2
Schizophrenia and Related Psychoses

(2021), pp. 1-224
Closed Access | Times Cited: 4
A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight
Ritvij Satodiya, Victoria R. Brown, Susan W. Njuguna, et al.
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 5, pp. 495-499
Closed Access | Times Cited: 3
New antipsychotic medication
Krzysztof Wojtasik-Bakalarz, Marcin Siwek
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 19-38
Open Access | Times Cited: 1
A redux of schizophrenia research in 2021
Satish Suhas, Urvakhsh Meherwan Mehta
Schizophrenia Research (2022) Vol. 243, pp. 458-461
Open Access | Times Cited: 1
Lumateperone in the treatment of psychiatric disorders – a review of the literature
Ada Kaczmarek, Wiktor Szymajda, Katarzyna Dettlaff
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 39-52
Open Access
Are Nurses Prescribing Lumateperone (Caplyta)?
Jeremy F. Mills
Issues in Mental Health Nursing (2021) Vol. 43, Iss. 1, pp. 91-93
Closed Access
Page 1

Scroll to top